Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x100px

Document › Details

Bicycle Therapeutics plc. (6/3/24). "Press Release: Bicycle Therapeutics to Participate in Upcoming Investor Conferences". Cambridge & Boston, MA.

	Organisation	Bicycle Therapeutics plc (Nasdaq: BCYC)
	Group	Bicycle Therapeutics (Group)
	Organisation 2	Jefferies LLC
	Group	Leucadia (Group)
	Product	Jefferies 2024 Global Healthcare Conference New York
	Product 2	Goldman Sachs Annual Global Healthcare Conference 2024 Miami
	Index term	Bicycle Therapeutics–Leucadia: investor conference, 202406 supply service Bicycle Tx at Jefferies 2024 Global Healthcare Conference
	Index term 2	Bicycle Therapeutics–Goldman Sachs: investor conference, 202406 supply service Bicycle Tx at GS Annual Global Healthcare Conference

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in the following investor conferences in June:

> Jefferies Global Healthcare Conference on Wednesday, June 5, 2024; fireside chat at 8:30 a.m. ET

> Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024; fireside chat at 1:20 p.m. ET

> TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit on Monday, June 17, 2024; fireside chat at 3:00 p.m. ET

Live webcasts of the fireside chats will be accessible in the Investor section of the Company’s website at www.bicycletherapeutics.com. Archived replays of the webcasts will be available following the fireside chat dates.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.

Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.

Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
ir@bicycletx.com
857-523-8544

Media:
Deborah Elson
Argot Partners
media@bicycletx.com
212-600-1902

Record changed: 2024-09-23